
Concord Biotech Sees Margin Gains Amid Procurement Delays
The story in brief
Concord Biotech, a leader in immunosuppressant drugs like Tacrolimus, Cyclosporine, and Mycophenolate, saw its gross margin improve to 76.7% year-on-year despite customers deferring procurement decisions due to tariff and geopolitical uncertainty. The company maintains a world-leading fermentation-based portfolio and significant spare capacity, positioning it well in a niche it has mastered for over 25 years.